1
|
Solano N, Castrillo A, Peraza A, Rivera E, Fuenmayor L. Implants P-65853023-398 Stepwise drilling protocol in dental implants for patients with low bone densities: Case report. Int J Oral Maxillofac Surg 2023. [DOI: 10.1016/j.ijom.2022.09.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
2
|
Bosque A, Howard J, Zaikos T, Levinger C, McMahon E, Takata H, Rivera E, Copertino D, Wang W, Sanz-Perez M, Arias-Moreno X, Soriano-Sarabia N, Jones RB, Trautmann L. OP 5.2 – 00070 Characterization of a dual PTPN1/PTPN2 inhibitor to target latent HIV reservoirs. J Virus Erad 2022. [DOI: 10.1016/j.jve.2022.100236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
3
|
Gavigan K, Rivera E, Curtis JR, Venkatachalam S, Stradford L, Curtis D, Nowell WB. POS0088-PARE CHANGES IN PATIENT-REPORTED OUTCOME SCORES DURING COVID-19 PANDEMIC: DATA FROM THE ArthritisPower REGISTRY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe COVID-19 pandemic causes concern among patients with autoimmune and rheumatic disease (ARD) due to increased risk of infection and heightened isolation from social distancing.1ObjectivesExamine how mean patient-reported outcome (PRO) scores for mental, social and physical health fluctuated after COVID-19 vaccine availability was widespread in US.MethodsWe conducted and reported on2 an initial analysis of January 2020 – April 2021 where US participants (pts) of the ArthritisPower (AP) registry completed PROMIS measures of physical health (Physical Function, Pain Interference, Fatigue, Sleep Disturbance), mental health (Anger, Anxiety, Depression) and social health (Social Isolation, Emotional Support). Follow-up analysis was conducted May – December 2021. Only pts from initial analysis were included in follow-up. Null hypothesis was no change in monthly average scores across 23-month pandemic period. Analysis of means compared monthly assessment mean scores to overall mean score for each measure during study period. Pts with < 2 assessment time points and osteoarthritis with no ARD were excluded from analysis.ResultsTotal of 49,940 PRO scores were contributed by 2,266 pts during 23-month period, with 8,393 of the scores contributed from May – December 2021. Mean (standard deviation, SD) number of observations per pt was 5.6 (12.5). Pts were 87.6% female, 86.7% white, mean age of 52.1 (12.7) years. Rheumatoid arthritis (n=1,131, 49.9%) was the most common condition. Most commonly reported measures were Pain Interference, Fatigue, Sleep Disturbance and Physical Function, each with >11,000 total results (Table 1).Table 1.Avg assessment scores+ by month, mean (SD)Pain Interf (n= 11536)Fatigue (n= 11591)Sleep Disturb (n= 11257)Physical Func (n= 11202)Depression (n=1489)Anxiety (n= 1066)Social Iso (n=698)Emot Support (n=578)Anger (n=523)Study Period^63.3 (7.8)62.6 (9.5)58.1 (9.0)37.7 (7.6)60.8 (9.2)62.4 (10.5)61.9 (10.2)40.8 (9.8)61.5 (12.8)May 202161.9 (8.2)*60.9 (9.7)*55.2 (8.8)*38.9 (8.5)59.5 (9.2)61.9 (9.8)60.2 (13.3)38.1 (8.3)59.6 (14.5)June61.6 (6.9)*60.9 (9.6)*54.8 (8.9)*38.3 (7.8)59.2 (7.0)60.6 (9.6)61.8 (12.0)39.3 (10.3)60.2 (10.9)July61.8 (7.4)*60.8 (10.2)*56.0 (8.6)*38.1 (7.9)61.0 (7.8)59.9 (12.1)66.8 (8.5)*39.4 (9.7)62.4 (9.7)Aug61.2 (8.5)*60.7 (10.4)*55.8 (9.6)*38.5 (8.5)57.7 (7.9)*58.2 (10.3)*57.2 (11.1)36.9 (12.2)53.3 (19.4)Sep62.4 (8.5)62.3 (10.0)56.2 (8.3)37.3 (7.6)58.7 (8.0)57.7 (11.3)*68.1 (12.8)36.7 (12.1)58.7 (12.0)Oct63.1 (8.4)63.3 (9.9)57.6 (8.6)37.3 (8.0)59.9 (9.9)62.3 (9.0)64.3 (10.3)37.3 (11.4)64.6 (10.2)Nov62.6 (6.8)63.2 (10.0)55.8 (8.6)*36.9 (7.0)59.1 (8.8)61.3 (6.8)61.4 (10.9)38.6 (11.7)60.3 (12.4)Dec62.9 (8.3)64.0 (9.6)56.5 (8.4)37.4 (8.1)60.7 (8.4)63.8 (5.3)65.1 (7.5)38.5 (13.5)68.6 (5.0)*+PROMIS measures scored 0-100; mean 50 for general US population; 1SD = 10 points^Study period: January 2020 – December 2021. *Statistical significance (p<0.05); analysis of means (ANOM)Pts’ mental and social health assessment scores improved then worsened during last 8 months of 2021 (Figure 1). Overall mean scores were: Anxiety 62.4 (12.5), Social Isolation 61.9 (10.5), and Anger 61.5 (12.8). From July – August, Social Isolation decreased by 1 SD. Compared to overall assessment mean, Anger declined by > ½ SD (53.3 [19.4]) in August and Anxiety declined by ½ SD (57.7 [11.3]) in September. By December, Anger rose by > ½ SD (68.6 [5.0]) of assessment mean. Pain Interference (mean: 63.3 [7.8]), Fatigue (62.6 [9.5]), and Sleep Disturbance (58.1 [9.0]) scores were significantly lower in May, June, July and August compared to the assessment mean, though none decreased by > ½ SD.ConclusionARD members of AP had mental, social and physical health scores improve during summer of 2021, corresponding with widespread availability of vaccines. However mental and social health scores worsened by December as US faced new variants of the virus.References[1]George M, et al. Rheumatol. 2021;48:603-7.[2]Gavigan K, et al. Arth Rheumatol. 2021;73(suppl 10).AcknowledgementsThis work was partially supported through a Patient-Centered Outcomes Research Institute (PCORI) award (PPRN-1306-04811). All statements in this poster, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee.Disclosure of InterestsKelly Gavigan: None declared, Esteban Rivera: None declared, Jeffrey R. Curtis Consultant of: Gilead, Novartis, and Samsung, Grant/research support from: AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, Shilpa Venkatachalam: None declared, Laura Stradford: None declared, David Curtis: None declared, W. Benjamin Nowell Grant/research support from: William B. Nowell is the Principal Investigator on grants/contracts from AbbVie, Eli Lilly and Company, and PCORI, and an employee of the Global Healthy Living Foundation (GHLF). GHLF receives grants, sponsorships and contracts from pharmaceutical manufacturers and private foundations. A full list of GHLF funders is publicly available here: https://www.ghlf.org/our-partners/.
Collapse
|
4
|
Valencia-May E, Rivera E, Novelo-Peralta O, Burillo G. Comparative analysis of two hydrogel architectures synthesized by gamma radiation based on dimethylacrylamide and acrylic acid grafted on polyethylene. Radiat Phys Chem Oxf Engl 1993 2022. [DOI: 10.1016/j.radphyschem.2022.109975] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
5
|
Holtzman LP, Blasi G, Rivera E, Herrero F, Downton K, Oates T. Gingival Thickness and Outcome of Periodontal Plastic Surgery Procedures: A Meta-regression Analysis. JDR Clin Trans Res 2020; 6:295-310. [PMID: 32718265 DOI: 10.1177/2380084420942171] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
OBJECTIVE To evaluate the impact of soft tissue thickness (STT) on root coverage achieved with different periodontal plastic surgery procedures. BACKGROUND Gingival recession has been managed successfully through various surgical approaches, with great variability in outcomes. Anatomic characteristics of the recipient site and selected technique account in part for this variability. Gingival flap thickness is one of the most critical site-related characteristics. METHODS An electronic search was conducted on the major databases (PubMed, Embase, Web of Science). Human prospective studies with at least 6 mo of follow-up and with a numeric baseline measurement for gingival thickness were eligible. Only studies including nonsmoking patients were considered. Variables included surgical approach, participant characteristics, local anatomic factors, and follow-up time. Primary outcome was mean percentage root coverage (%RC) achieved, and complete root coverage was a secondary outcome. RESULTS A total of 42 studies were included (35 randomized controlled trials, 5 case series, 1 prospective cohort study, and 1 controlled clinical trial). Across studies, the pooled %RC was 81.9% (95% CI, 79.1% to 84.7%). The %RC was not significantly associated (P = 0.267) with baseline soft tissue thickness; however there was a significant (P = 0.031) inverse relationship between STT and %RC after 12-mo follow-up. Subgroup analysis showed that for no graft, there was a significant (P = 0.025) positive relationship between STT and %RC with the exclusion of the single outlier study based on STT. CONCLUSIONS STT plays a limited role in predicting root coverage across all approaches; when flaps are performed with no graft, the effect of STT is most critical. The length of time following surgery appears to influence outcomes, with 12-mo follow-up offering greater insight. KNOWLEDGE TRANSFER STATEMENT The results of this study can suggest to clinicians which periodontal plastic surgery technique to employ when treating challenging cases. In particular, it can be helpful when selecting the treatment approach to treat thin phenotype sites. This study could help clinicians provide a more appropriate treatment decision in such cases.
Collapse
Affiliation(s)
- L Paternò Holtzman
- Department of Periodontology and Prosthodontics, G. Eastman Dental Hospital, Rome, Italy.,Private practice, Rome, Italy.,Division of Periodontics, Department of Advanced Oral Sciences and Therapeutics, School of Dentistry, University of Maryland, Baltimore, MD, USA
| | - G Blasi
- Division of Periodontics, Department of Advanced Oral Sciences and Therapeutics, School of Dentistry, University of Maryland, Baltimore, MD, USA.,Department of Periodontology, International University of Catalonia, Barcelona, Spain
| | - E Rivera
- Division of Periodontics, Department of Advanced Oral Sciences and Therapeutics, School of Dentistry, University of Maryland, Baltimore, MD, USA
| | - F Herrero
- Division of Periodontics, Department of Advanced Oral Sciences and Therapeutics, School of Dentistry, University of Maryland, Baltimore, MD, USA.,Private practice, San Juan, Puerto Rico
| | - K Downton
- Health Sciences and Human Services Library, University of Maryland, Baltimore, Baltimore, MD, USA
| | - T Oates
- Division of Periodontics, Department of Advanced Oral Sciences and Therapeutics, School of Dentistry, University of Maryland, Baltimore, MD, USA
| |
Collapse
|
6
|
Fernandez J, Alfaro T, Martine G, Rivera E, Oksenberg S, Pichon J, Fica M. P2.06-24 Mesothelioma Survival in 2 Health Centres in Santiago de Chile. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
7
|
Seijas R, Rius M, Barastegui D, Ares O, Rivera E, Alvarez-Diaz P. Sonographic Measurement of the Patellar Tendon Should Predict Autograft Bone Patellar Tendon Bone (BPTB) Size: Comparison of Anatomical and Clinical Findings. J INVEST SURG 2019; 33:621-626. [PMID: 30730225 DOI: 10.1080/08941939.2018.1551949] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The use of BPTB autograft is frequently used in ACL reconstruction, however, the risk of potential failure in patients with an anatomically unfavorable patellar tendon may predispose to reconstruction failure. Anatomical study of the extensor apparatus of the knee can provide knowledge about the best option obtain the graft and perform a better preoperative planning. Musculoskeletal ultrasound is a simple, reproducible, affordable technique that could be valid for patellar tendon evaluation. The objective of this study is to evaluate the reproducibility of the patellar tendon measurements by ultrasound and compare them with anatomical measurements, both in cadaver and patients undergoing ACLR. The study consists of two phases; first anatomical study in cadaver. The ultrasound measurement was performed by determining the length, width and thickness of the patellar tendon, both by ultrasound and anatomical dissection. The second phase is a cohort of 42 patients pending surgical ACLR. Previous ultrasound and intraoperative measurements were obtained. Regarding the anatomical study, statistical analysis did not show any differences comparing the measurements in length (p = ns) and thickness (p = ns) of the patellar tendon, although differences were obtained when comparing the results obtained for the width of the tendon after the ultrasound and anatomical measurement (p < 0.001). Same results were obtained in second phase of the study. The reproducibility of ultrasound measurements of the PT is comparable to intraoperatively measurements (without width measurement). These findings can be useful for preoperative planning in the reconstruction of ACL with BPTB Graft and to assess technical modifications prior to surgery.
Collapse
Affiliation(s)
- R Seijas
- Artroscopia GC. Fundación García Cugat, Barcelona, Spain.,Hospital Quirón Barcelona, Barcelona, Spain.,Universitat Internacional de Catalunya, Sant Cugat del Valles, Spain
| | - M Rius
- Artroscopia GC. Fundación García Cugat, Barcelona, Spain.,Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes. FCF-RFEF, Barcelona, Spain.,Hospital Teknon Barcelona, Barcelona, Spain
| | - D Barastegui
- Artroscopia GC. Fundación García Cugat, Barcelona, Spain.,Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes. FCF-RFEF, Barcelona, Spain
| | - O Ares
- Universitat Internacional de Catalunya, Sant Cugat del Valles, Spain.,Hospital Teknon Barcelona, Barcelona, Spain
| | - E Rivera
- Artroscopia GC. Fundación García Cugat, Barcelona, Spain.,Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes. FCF-RFEF, Barcelona, Spain
| | - P Alvarez-Diaz
- Artroscopia GC. Fundación García Cugat, Barcelona, Spain.,Hospital Quirón Barcelona, Barcelona, Spain.,Universitat Internacional de Catalunya, Sant Cugat del Valles, Spain.,Mutualitat Catalana de Futbolistes. FCF-RFEF, Barcelona, Spain
| |
Collapse
|
8
|
Barastegui D, Seijas R, Alvarez-Diaz P, Rivera E, Alentorn-Geli E, Steinbacher G, Cuscó X, Cugat R. Assessing long-term return to play after hip arthroscopy in football players evaluating risk factors for good prognosis. Knee Surg Sports Traumatol Arthrosc 2018; 26:963-968. [PMID: 28516234 DOI: 10.1007/s00167-017-4573-z] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Accepted: 05/12/2017] [Indexed: 10/19/2022]
Abstract
PURPOSE Groin pain is the third most common disease in football players and has often been associated with hip pathology such as femoroacetabular impingement and labral lesions. Hip arthroscopy offers possibilities of function restoration via minimally invasive procedures. The aim of this study is to evaluate professional football player's injuries and their return to play after hip arthroscopy for FAI and labral injuries. METHODS Patients that underwent hip arthroscopy between 2009 and 2014 were selected retrospectively. From this population, only professional soccer players competing at national level were included (Tegner 10). Arthroscopic surgery was proposed in patients with persistent pain. All patients were assessed for VAS score preoperatively and at 3, 6, 12 and 24 months post-op. HOS (sport and DLA) and mHHS tests were performed at the same time periods. RESULTS All patients were men with a mean age of 26.5 ± 7.1 years old. Preoperative VAS (7.4 ± 1.3), HOS ADL (67.7 ± 5.5), HOS sport (37.6 ± 18.7) and mHHS (72.5 ± 8.8) showed improved scores during long-term follow-up. Time to return to play was 10.8 months (SD ± 4.3), with range between 4 and 20 months. Mean follow-up was 45.4 ± 15.6 months (range from 26 to 72 months). No differences were observed between non-active and active patients at final follow-up with respect to chondral lesions, but significant differences were observed with reference to management of the labrum (p = 0.031), where a higher rate of labrectomies existed among inactive patients and a higher rate of suture among active patients. CONCLUSIONS Hip arthroscopy is a safe procedure with very good return to play results, but for optimized return to football one should consider patient age at the time of surgery, the condition of the labrum and low scores on the Harris Hip Score (mHHS) and HOS (sport version) as predictive factors for poor prognosis. Level of evidence IV.
Collapse
Affiliation(s)
- D Barastegui
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain
| | - R Seijas
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain. .,Universitat Internacional de Catalunya, Barcelona, Spain.
| | - P Alvarez-Diaz
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain.,Universitat Internacional de Catalunya, Barcelona, Spain
| | - E Rivera
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain
| | - E Alentorn-Geli
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain
| | - G Steinbacher
- Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain
| | - X Cuscó
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain
| | - R Cugat
- Artroscopia GC, Fundación García Cugat, Hospital Quirón Barcelona, Barcelona, Spain.,Mutualitat Catalana de Futbolistes, Federación Española de Fútbol-RFEF, Barcelona, Spain
| |
Collapse
|
9
|
Rivera E, Hernandez R, Carissimi AS, Pekow C. Laboratory Animal Legislation in Latin America. ILAR J 2017; 57:293-300. [PMID: 29117400 DOI: 10.1093/ilar/ilw017] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2016] [Accepted: 06/22/2016] [Indexed: 01/08/2023] Open
Abstract
A review of existing legislation covering laboratory animals in Latin America is presented. The region presents a spectrum of economic development, political stability, and cultural diversity. With the exception of a few nations, there is a lack of regulations as well as minimal enforcement of existing laws pertaining to laboratory animals. Brazil, Mexico, and Uruguay stand out as the only nations in this region with specific legislation regulating laboratory animal care and use; the history and current status of regulations in these three nations is reviewed.
Collapse
Affiliation(s)
- E Rivera
- Laboratory Animal House, University of Goias. Universidade Federal de Goias - Campus Samambaia - Instituto de Ciencias Biologicas Golania, GO Brazil. Universidad Nacional Autonoma de Mexico - FACULTAD DE VETERINARIA, Coyoacan, Distrito Federal Mexico. Universidade Federal do Rio Grande do Sul - FACULDADE DE VETERINARIA, Porto Alegre, RS Brazil. Veterinary Medical Unit Veterans Affairs Puget Sound Health Care System Seattle, Washington
| | - R Hernandez
- Laboratory Animal House, University of Goias. Universidade Federal de Goias - Campus Samambaia - Instituto de Ciencias Biologicas Golania, GO Brazil. Universidad Nacional Autonoma de Mexico - FACULTAD DE VETERINARIA, Coyoacan, Distrito Federal Mexico. Universidade Federal do Rio Grande do Sul - FACULDADE DE VETERINARIA, Porto Alegre, RS Brazil. Veterinary Medical Unit Veterans Affairs Puget Sound Health Care System Seattle, Washington
| | - A S Carissimi
- Laboratory Animal House, University of Goias. Universidade Federal de Goias - Campus Samambaia - Instituto de Ciencias Biologicas Golania, GO Brazil. Universidad Nacional Autonoma de Mexico - FACULTAD DE VETERINARIA, Coyoacan, Distrito Federal Mexico. Universidade Federal do Rio Grande do Sul - FACULDADE DE VETERINARIA, Porto Alegre, RS Brazil. Veterinary Medical Unit Veterans Affairs Puget Sound Health Care System Seattle, Washington
| | - C Pekow
- Laboratory Animal House, University of Goias. Universidade Federal de Goias - Campus Samambaia - Instituto de Ciencias Biologicas Golania, GO Brazil. Universidad Nacional Autonoma de Mexico - FACULTAD DE VETERINARIA, Coyoacan, Distrito Federal Mexico. Universidade Federal do Rio Grande do Sul - FACULDADE DE VETERINARIA, Porto Alegre, RS Brazil. Veterinary Medical Unit Veterans Affairs Puget Sound Health Care System Seattle, Washington
| |
Collapse
|
10
|
Amodeo DA, Rivera E, Cook EH, Sweeney JA, Ragozzino ME. 5HT 2A receptor blockade in dorsomedial striatum reduces repetitive behaviors in BTBR mice. Genes Brain Behav 2016; 16:342-351. [PMID: 27717169 DOI: 10.1111/gbb.12343] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 09/17/2016] [Accepted: 09/19/2016] [Indexed: 12/01/2022]
Abstract
Restricted and repetitive behaviors are a defining feature of autism, which can be expressed as a cognitive flexibility deficit or stereotyped, motor behaviors. There is limited knowledge about the underlying neuropathophysiology contributing to these behaviors. Previous findings suggest that central 5HT2A receptor activity is altered in autism, while recent work indicates that systemic 5HT2A receptor antagonist treatment reduces repetitive behaviors in an idiopathic model of autism. 5HT2A receptors are expressed in the orbitofrontal cortex and striatum. These two regions have been shown to be altered in autism. The present study investigated whether 5HT2A receptor blockade in the dorsomedial striatum or orbitofrontal cortex in the BTBR mouse strain, an idiopathic model of autism, affects the phenotype related to restricted and repetitive behaviors. Microinfusion of the 5HT2A receptor antagonist, M100907 into the dorsomedial striatum alleviated a reversal learning impairment and attenuated grooming behavior. M100907 infusion into the orbitofrontal cortex increased perseveration during reversal learning and potentiated grooming. These findings suggest that increased 5HT2A receptor activity in the dorsomedial striatum may contribute to behavioral inflexibility and stereotyped behaviors in the BTBR mouse. 5HT2A receptor signaling in the orbitofrontal cortex may be critical for inhibiting a previously learned response during reversal learning and expression of stereotyped behavior. The present results suggest which brain areas exhibit abnormalities underlying repetitive behaviors in an idiopathic mouse model of autism, as well as which brain areas systemic treatment with M100907 may principally act on in BTBR mice to attenuate repetitive behaviors.
Collapse
Affiliation(s)
- D A Amodeo
- Department of Psychology, University of Illinois at Chicago
| | - E Rivera
- Department of Psychology, University of Illinois at Chicago
| | - E H Cook
- Institute of Juvenile Research, University of Illinois at Chicago, Chicago, IL
| | - J A Sweeney
- Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - M E Ragozzino
- Department of Psychology, University of Illinois at Chicago
| |
Collapse
|
11
|
Tsotsoros SD, Lutz PB, Daniel AG, Peterson EJ, de Paiva REF, Rivera E, Qu Y, Bayse CA, Farrell NP. Enhancement of the physicochemical properties of [Pt(dien)(nucleobase)] 2+ for HIVNCp7 targeting. Chem Sci 2016; 8:1269-1281. [PMID: 28451269 PMCID: PMC5369524 DOI: 10.1039/c6sc03445d] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Accepted: 10/06/2016] [Indexed: 12/31/2022] Open
Abstract
Physicochemical properties of coordination compounds can be exploited for molecular recognition of biomolecules. The inherent π-π stacking properties of [Pt(chelate)(N-donor)]2+ ([PtN4]) complexes were modulated by systematic variation of the chelate (diethylenetriamine and substituted derivatives) and N-donor (nucleobase or nucleoside) in the formally substitution-inert PtN4 coordination sphere. Approaches to target the HIV nucleocapsid protein HIVNCp7 are summarized building on (i) assessment of stacking interactions with simple tryptophan or tryptophan derivatives to (ii) the tryptophan-containing C-terminal zinc finger and (iii) to the full two-zinc finger peptide and its interactions with RNA and DNA. The xanthosine nucleoside was identified as having significantly enhanced stacking capability over guanosine. Correlation of the LUMO energies of the modified nucleobases with the DFT π-stacking energies shows that frontier orbital energies of the individual monomers can be used as a first estimate of the π-stacking strength to Trp. Cellular accumulation studies showed no significant correlation with lipophilicity of the compounds, but all compounds had very low cytotoxicity suggesting the potential for antiviral selectivity. The conceptual similarities between nucleobase alkylation and platination validates the design of formally substitution-inert coordination complexes as weak Lewis acid electrophiles for selective peptide targeting.
Collapse
Affiliation(s)
- S D Tsotsoros
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA .
| | - P B Lutz
- Department of Science , Technology and Mathematics , Regent University , Virginia Beach , Virginia 23464 , USA.,Department of Chemistry and Biochemistry , Old Dominion University , Norfolk , VA 23529 , USA .
| | - A G Daniel
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA .
| | - E J Peterson
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA . .,Massey Cancer Center , Virginia Commonwealth University , Richmond , VA , USA
| | - R E F de Paiva
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA .
| | - E Rivera
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA .
| | - Y Qu
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA .
| | - C A Bayse
- Department of Chemistry and Biochemistry , Old Dominion University , Norfolk , VA 23529 , USA .
| | - N P Farrell
- Department of Chemistry , Virginia Commonwealth University , 1001 W. Main Street , Richmond , VA 23284-2006 , USA . .,Massey Cancer Center , Virginia Commonwealth University , Richmond , VA , USA
| |
Collapse
|
12
|
Bivalacqua T, Steinberg G, Smith N, Lerner S, Bochner B, Lee C, Rivera E, Jain D, Bertram T, Schoenberg M. 178 Pre-clinical and clinical translation of a tissue engineered neo–urinary conduit using adipose derived smooth muscle cells for urinary reconstruction. ACTA ACUST UNITED AC 2014. [DOI: 10.1016/s1569-9056(14)60177-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Affiliation(s)
- E Rivera
- Section of Gastroenterology; Hepatology and Nutrition Department of Pediatrics; University of Chicago; Chicago; IL; USA
| | - A Assiri
- Pediatric Gastroenterology; Faculty of Medicine; King Khalid University Hospital; King Saud University; Riyadh; Saudi Arabia
| | | |
Collapse
|
14
|
Rivera E, Chang JC, Semiglazov V, Gorbunova V, Manikhas A, Krasnozhon D, Kirby G, Spector T. Abstract OT3-3-01: Eniluracil + 5-fluorouracil + leucovorin (EFL) vs. capecitabine phase 2 trial for metastatic breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-ot3-3-01] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Based on a modified dosing protocol designed to optimize efficacy, an open-label EFL vs. capecitabine (4:3 randomization) Phase 2 trial for metastatic breast cancer is in progress. Eniluracil inactivates dihydropyrimidine dehydrogenase, thereby preventing the formation of α-fluoro-β-alanine, and conferring 100% oral bioavailability and a 5 hr half-life on 5-fluorouracil (5-FU). Study drugs are administered orally for 1st- or 2nd-line treatment for metastatic disease in patients previously treated with an anthracycline and a taxane. Arm 1: eniluracil (40 mg) taken 11–16 hr before 5-FU (30 mg/m2); leucovorin (30 mg) taken with 5-FU and the next day. The regimen is administered once/week for 3 weeks/4 weeks. Arm 2: capecitabine (1000 mg/m2) taken bid for 14 days/21days. Arm 2 patients with disease progression could crossover to take EFL in Arm X. Two sites in the USA and 19 in Russia are enrolling. Currently, 115 patients (21% are 1st-line, 70% had previous 5-FU treatment) are enrolled and 83 have had tumor assessments. EFL was well tolerated with no unexpected toxicities. As of May 2012, there were 11, 7, & 1 partial responses in Arms 1, 2, & X, respectively. The primary endpoint, progression-free survival, will be determined approximately 7.5 months after the trial is enrolled with 140 evaluable patients.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr OT3-3-01.
Collapse
Affiliation(s)
- E Rivera
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - JC Chang
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - V Semiglazov
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - V Gorbunova
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - A Manikhas
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - D Krasnozhon
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - G Kirby
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| | - T Spector
- Banner MD Anderson Cancer Center, Gilbert, AZ; The Methodist Hospital Research Institute, Houston, TX; Road Clinical Hospital of the Russian Railways, St. Petersburg, Russian Federation; Russian Oncological Research Center n.s. Blokhin RAMS, Moscow, Russian Federation; City Clinical Oncology Center, St. Petersburg, Russian Federation; Institution Leningrad Regional Oncology Center, Leningrad Region, Russian Federation; Adherex Technologies, Inc., Research Triangle Park, NC
| |
Collapse
|
15
|
Sanchez J, Rivera E, Rosales L, Baldeviano G, Asencios J, Burrus R, Vinetz J, Edgel K, Lescano A. Epidemiology of malaria in gold mining camps, Madre de Dios, Peru. Int J Infect Dis 2012. [DOI: 10.1016/j.ijid.2012.05.705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
16
|
Nevadunsky N, Brodt Z, Eti S, Rapkin B, Rivera E, Selwyn P, Goldberg G. Differences in the use of palliative medicine consultation in gynecologic malignancies in an urban hospital system. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Generali D, Nguyen B, Deck K, Kerlin D, Garcia A, Barone J, Rivera E, Yao K, Stork-Sloots L. 346 Comparison of Molecular Subtyping with BluePrint and MammaPrint to Local IHC/FISH Based Subtype Classification According to St Gallen 2011 in 133 Breast Cancer Patients. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70412-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Nguyen B, Deck KB, Sinha R, Kerlin D, Barone J, Rivera E, Garcia A, Yao K, Stork-Sloots L. Comparison of MammaPrint, BluePrint, and TargetPrint with clinical parameters in patients with breast cancer: Findings from a prospective United States cohort. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.27_suppl.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
47 Background: MammaPrint (MP) is a powerful predictor of disease outcome in early stage breast cancer. In addition, TargetPrint (TP), a microarray-based test that measures the mRNA expression level of ER, PR and HER2 and an 80 gene expression Molecular Subtyping profile BluePrint (BP) were developed. In the present study, MP, BP and TP were measured in a prospective U.S. breast cancer patient cohort. Methods: MP results were evaluated in fresh tumor samples from 127 breast cancer patients (T1-4N0-2; median age 62 [39-97 yr]) collected by core needle biopsy or from a surgical specimen between July 2008 and January 2011. We compared treatment advice as recommended by NCCN guidelines and classification according to MP. In addition, we compared IHC/FISH ER, PR and HER2 assessments with TP. The MP and BP results were used to subtype the patients into molecular subgroups. Results: For the group of patients (n=59) for which NCCN recommends the use of a multi-gene signature for determining chemotherapy treatment recommendations, 42 patients were classified as High Risk and 17 as Low Risk by MP. Comparison of TP with IHC/FISH indicated a concordance of 98% for ER, 94% for PR, and 98% for HER2. For a subgroup of 53 patients combined MP and BP results were available; 18 patients were Luminal-type/MP Low Risk, 27 patients were Luminal-type/MP High risk, 1 patient was Her2-type/MP Low Risk, 1 patient was Her2-type/MP High Risk and 6 patients were Basal-type/MP High Risk. Conclusions: Adding the multi-gene signature MammaPrint, as well as BluePrint and TargetPrint provides additional information for treatment guidance. By combining MammaPrint with the BluePrint molecular subtyping profile, specific groups of patients can be recognized that are at high risk of recurrence and that would possibly benefit from specific treatment. This study shows that TargetPrint provides high quality second opinion for local IHC/FISH assessment.
Collapse
Affiliation(s)
- B. Nguyen
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - K. B. Deck
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - R. Sinha
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - D. Kerlin
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - J. Barone
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - E. Rivera
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - A. Garcia
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - K. Yao
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| | - L. Stork-Sloots
- Long Beach Memorial Health Care, Long Beach, CA; South Orange County Surgical Medical Group, Laguna Hills, CA; Rockwood Clinic, Spokane Valley, WA; John Muir Hospital, Walnut Creek, CA; Comprehensive Breast Care of San Diego and Sharp Memorial Hospital, San Diego, CA; Methodist Hospital/Weill Cornell University, Houston, TX; University of Southern California Keck School of Medicine, Los Angeles, CA; NorthShore University HealthSystem, Evanston, IL; Agendia, Irvine, CA
| |
Collapse
|
19
|
Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O’Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs 2011; 30:1942-9. [DOI: 10.1007/s10637-011-9747-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2011] [Accepted: 08/30/2011] [Indexed: 10/17/2022]
|
20
|
Deck KB, Sinha R, Kerlin D, Barone J, Rivera E, Garcia AA, Yao K, Stork-Sloots L, Bender RA, Nguyen B. Comparison of MammaPrint and TargetPrint with clinical parameters in patients with breast cancer: Findings from a prospective U.S. cohort. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Cotto M, Cabanillas F, Garcia-Manero G, Yang H, Bruno M, Pavia OA, Rivera E, Liboy I, Tirado-Gomez M. Epigenetic therapy with valproic acid, an HDAC inhibitor, in refractory/relapsed non-Hodgkin lymphoma (NHL) and Hodgkin disease. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Bayne K, Bayvel D, Clark JM, Demers G, Joubert C, Kurosawa TM, Rivera E, Souilem O, Turner PV. Harmonizing Veterinary Training and Qualifications in Laboratory Animal Medicine: A Global Perspective. ILAR J 2011; 52:393-403. [DOI: 10.1093/ilar.52.3.393] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Cotto M, Toro J, Carlo V, Vaquer R, Pavia OA, Bruno M, Rivera E, Echenique MM, Negron V, Cabanillas F. Comparison of first-course PET scan against fourth-course MRI for early detection of poor responders to neoadjuvant chemotherapy (NAC) for breast cancer (BC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.564] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Montalvo S, Guerrero L, Rivera E, Borja R, Chica A, Martín A. Kinetic evaluation and performance of pilot-scale fed-batch aerated lagoons treating winery wastewaters. Bioresour Technol 2010; 101:3452-3456. [PMID: 20097559 DOI: 10.1016/j.biortech.2009.12.101] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2009] [Revised: 12/21/2009] [Accepted: 12/22/2009] [Indexed: 05/28/2023]
Abstract
Winery wastewater was treated in two pilot-scale aerated lagoons operating in fed-batch mode. A first lagoon of 27.2m(3) working volume was gradually filled with wastewater with an average COD content of 8700mg/L. Given that with the flow-rate used (790L/day) this first lagoon completed its working volume after 30days of starting, part of the liquid contained in the first lagoon was transferred to another adjacent second lagoon of 10.8m(3) working volume. Therefore, the experiment continued in the second lagoon for another additional 24days using an influent with a COD content of 18,700mg/L at a flow-rate of 170L/day. After the 21st day, a maximum COD removal efficiency of 91% was achieved, and this value was maintained virtually constant until the end of the experiments. A mathematical model based on three differential equations solved simultaneously allowed the kinetic parameters of the system to be obtained.
Collapse
Affiliation(s)
- S Montalvo
- Departamento de Ingeniería Química, Universidad de Santiago de Chile, Avenida Libertador Bernardo O'Higgins 3363, Santiago de Chile, Chile
| | | | | | | | | | | |
Collapse
|
25
|
Moulder SL, Rivera E, Ensor J, Gonzalez-Angulo A, Christofanilli M, Booser D, Giordano S, Brewster A, Hortobagyi G, Tran H. Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.1066] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1066 Background: Inhibition of mTOR with everolimus (E) may improve efficacy in combination with docetaxel (D), but both drugs are metabolized by CYP3A4, thus a pharmacokinetic (PK) interaction may also exist. Methods: 15 patients (pts) with MBC were treated with docetaxel and everolimus using the continuous reassessment method (CRM) to determine maximum tolerated dose (MTD). Docetaxel doses were 40–75 mg/m2 IV on day 1 of a 21 day cycle. Everolimus doses were 20–50 mg PO on days 1 and 8 of a 21 day cycle (except cycle 2, where only day 8 was given to allow single agent PK analyses of both drugs). Response was measured every 2 cycles using RECIST. Results: Median age= 58 years and 77% of pts had >2 prior chemotherapies for MBC. Initially 2 of 2 pts treated (D= 75 mg/m2, E= 30 mg) developed DLT (neutropenic fever/infection), prompting a mandatory PK evaluation for all pts enrolled in subsequent cohorts. A second cohort of 3 patients (D=60 mg/m2, E=20mg) had no DLT, but no pts received day 8 of E due to grade 3–4 neutropenia. PK analyses demonstrated a 42% lowered (-42%) D clearance at the 60 mg/m2 in the presence of E (n=1). Subsequent cohorts were accrued at D=40 mg/m2 with escalating doses of E (Table). For the entire group, an 18% decrease (-18%) in D clearance was observed when D was administered concomitantly with E. High interpatient variability of D clearance was observed (range +16% to -135%). No pts had CR/PR, but 6 had SD>4 cycles and 2 had SD=8 cycles. Conclusions: Weekly everolimus appears to cause widely variable and unpredictable changes in docetaxel clearance making this combination unfeasible. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. L. Moulder
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - E. Rivera
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - J. Ensor
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - A. Gonzalez-Angulo
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - M. Christofanilli
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - D. Booser
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - S. Giordano
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - A. Brewster
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - G. Hortobagyi
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| | - H. Tran
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital, Houston, TX
| |
Collapse
|
26
|
Macías S, Castellano J, Vélez M, Hernández L, Rivera E, Rodríguez A. Luxación recidivante postraumática del tendón extensor carpi ulnaris (ECU) en la muñeca: a propósito de un caso. Rev Iberoam Cir Mano 2009. [DOI: 10.1055/s-0037-1606747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
La luxación o subluxación del tendón del extensor carpi ulnaris es uno de los diagnósticos diferenciales, a tener en cuenta, ante la existencia de dolor en el lado cubital de la muñeca, siendo rara su lesión aislada, por lo que su diagnóstico, puede pasar, con frecuencia, desapercibido.La lesión ocurre durante una hipersupinación del antebrazo, desviación cubital y flexión palmar de la muñeca. Manifestando el paciente la sintomatología dolorosa tras la reducción del tendón con la pronación, dolor que puede llegar a ser muy incapacitante, con disminución del movimiento de pronosupinación de la muñeca, y disminución de fuerza. Debido a su mecanismo de producción y aparición de los síntomas, el diagnóstico es clínico, pues las pruebas complementarias pueden ser normales. La luxación del tendón, sólo ocurre, ante la ruptura o desinserción de su vaina osteofibrosa propia, o capa profunda del sexto compartimento extensor, a pesar de que el ligamento anular dorsal, o capa superficial del retináculo extensor, permanezca intacto. El tratamiento ha de ser quirúrgico, para reconstruir la vaina o corredera osteofibrosa, obteniéndose resultados satisfactorios.
Collapse
Affiliation(s)
- S.M. Macías
- Especialista en Traumatología y Cirugía Ortopédica. Fremap-Gran Canaria FREMAP-Gran Canaria (Patología del Miembro Superior)
| | - J. Castellano
- Especialista en Traumatología Y Cirugía Ortopédica FEA del Servicio de Traumatología del H.U.I. de Gran Canaria FREMAP-Gran Canaria (Patología del Miembro Superior)
| | - M. Vélez
- Miem bro del Servicio de COT del H.U.I. de Gran Canaria FREMAP-Gran Canaria (Patología del Miembro Superior)
| | - L. Hernández
- Médico Asistencial de la UPS de FREMAP-Lanzarote FREMAP-Gran Canaria (Patología del Miembro Superior)
| | - E. Rivera
- Fisioterape uta de la UPS de FREMAP-Lanzarote FREMAP-Gran Canaria (Patología del Miembro Superior)
| | - A. Rodríguez
- Fisioterape uta de la UPS de FREMAP-Lanzarote FREMAP-Gran Canaria (Patología del Miembro Superior)
| |
Collapse
|
27
|
Cabanillas F, Liboy I, Rodriguez-Monge E, Pavia O, Robles N, Maldonado N, Rivera E, Torres I, Perdomo J, Acaba L. GROC (gemcitabine, rituximab, oxaliplatin combination) plus pegfilgrastim is less toxic and as active as DHAP and ESHAP for relapsed aggressive non-Hodgkin’s lymphoma (NHL). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8530] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Crescenti EJ, Medina V, Croci M, Bergoc R, Sanchez-Jimenez F, Rivera E. Gene expression profiles involved in survival and progression pathways modulated by oligoelements and lachesis muta venom in MDA-MB-231 breast cancer cells using expression macroarray analysis. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.22192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Cricco G, Medina V, Núñez M, Mohamad N, Gutiérrez A, Bergoc R, Rivera E, Martín G. Nitric oxide involvement in histamine-mediated PANC-1 cells growth. Inflamm Res 2007; 56 Suppl 1:S39-40. [PMID: 17806172 DOI: 10.1007/s00011-006-0519-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- G Cricco
- Radioisotopes Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956 PB (C 1113AAB), Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Cabanillas F, Pavia O, Rivera E, Liboy I. Dose-seeking study of the combination of GM-CSF with pegfilgrastim plus CHOP-rituximab in patients with aggressive non- Hodgkin lymphoma (NHL). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18501 Background: Therapy for aggressive B cell NHL includes CHOP-rituximab (CHOP-R)q 14 days with G-CSF support. We are now investigating CHOP-R plus pegfilgrastim (Neulasta [N]) and low dose GM-CSF (Leukine). The rationale for low dose GM-CSF is based on its stimulation of ADCC which appears to be the most important mechanism of action of R and upregulation of CD20 on B cells, in addition, to other immunomodulating effects. Some of these are seen at lower levels of GM-CSF and appear to be lost at higher doses. N is given in order to allow delivery of chemotherapy q. 2 weeks. Methods: The goal was to determine the optimal dose of GM-CSF needed to support absolute neutrophil count (ANC) recovery >1,000 by day 14 without inducing marked leucocytosis when combined with N. R is given on day 1, CHOP on day 2 and growth factors start on day 3. We used a single fixed low dose of N 3 mg s.c. on day 3 and an escalating dose of GM-CSF starting at 75 mcg s.c. on day 3. GM-CSF was repeated every Monday, Wednesday and Friday. Results: So far we have delivered 65 evaluable courses to 18 pts (16 evaluable) whose median age was 58 (range 26–87). The plan was to escalate GM-CSF as necessary to support ANC recovery by day 14 without inducing severe leucocytosis. GM-CSF was to be escalated in cohorts of 5 patients at: 75, 125 and 250 mcg. The first cohort of 5 was treated at 75 mcg and all 5 recovered their ANC to >1,000 by day 14 and none exceeded ANC >50,000 before day 14. Therefore the next cohort of 5 received the same dose of 75 and all 5 were able to recover by day 14. Subsequently the next 6 were also treated at the same dose of 75 mcg. During 65 total courses, all but 3 pts recovered ANC to >1,000 before day 14. Chemotherapy doses were not reduced unless severe infection (i.e. septic shock or bilateral pneumonia). Because of prolonged or severe neutropenia, intrapatient dose escalations of GM-CSF were done in 2 pts (to 125 mcg) during the 2nd course and to 250 mcg in 1 pt during the 3rd. Conclusions: GM- CSF 75 mcg on Mondays, Wednesdays and Fridays is adequate and safe to support ANC recovery if combined with 3 mg N. However, in view of encouraging data of McLaughlin et al with 250 mcg of Leukine plus R in indolent NHL, in the next study we will attempt to escalate Leukine to 250 mcg. [Table: see text]
Collapse
Affiliation(s)
| | - O. Pavia
- Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
| | - E. Rivera
- Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
| | - I. Liboy
- Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
| |
Collapse
|
31
|
Carlson RW, Schurman CM, Rivera E, Chung CT, Phan SC, Dice EK, Thomas E, Valero V. Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.1030] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1030 Background: Aromatase inhibitors (AIs) are highly active in postmenopausal women with hormone receptor positive breast cancer. However, the AIs do not suppress ovarian estrogen synthesis and are not effective in premenopausal women. This phase II study was initiated to estimate the activity of anastrozole when given with ovarian suppression by goserelin in premenopausal women with ER and/or PgR positive metastatic breast cancer. Methods: Premenopausal women with measurable recurrent or metastatic, ER and/or PgR positive breast cancer; no prior AI or LH-RH agonist/antagonist; no adjuvant chemotherapy within 6 months; ECOG performance status of 0–2; adequate organ function; and who provided signed, informed consent were eligible. A 2 stage phase II design was utilized. Treatment was with goserelin 3.6 mg SQ q4wk and anastrozole 1 mg/day begun on day 22 of protocol treatment. Treatment was continued to disease progression. Results: 35 patients (pts) were enrolled. Three were excluded from analysis for the following: 1 postmenopausal, 1 consent withdrawal, 1 early oophorectomy. Of the remaining 32 pts, median age was 43 yrs (range 26–51 yrs), 18 (56%) had prior chemotherapy, and 9 (28%) had prior SERM. Pts were Asian/Middle Eastern 22%, Caucasian 62%, Black 13%, Hispanic 3%. Disease sites were lymph node 50%, breast 44%, bone 81%, lung 41%, liver 22%, pleural effusion 6% and soft tissue 6%. Receptor status was ER+/PgR+ 75%, ER+/PgR- 22% and ER-/PgR+ 3%. Response: Treatment resulted in complete response (CR) in 1(3%), partial response (PR) in 11(34%), stable disease 6+ mos (SD) in 11(34%), and clinical benefit (CR+PR+SD) 23 (72%). Median TTP was 8 mos (range 2 - 63+ mos); median OS was 26 mos (range 11 - 63+ mos). Estradiol levels were detectable in 30/31 pts at baseline (median 56 pg/ml, range <10 - 273 pg/ml). Mean estradiol levels (pg/ml) were 75 at baseline, 21 at 1 mos, 19 at 3 mos, and 15 at 6 mos. TOXICITY: One grade 3 weight loss. All other toxicities were grade 1–2. Conclusions: Ovarian suppression with goserelin in combination with anastrozole is well tolerated and highly active in the treatment of premenopausal, hormone receptor-positive metastatic breast cancer. Support provided by AstraZeneca Pharmaceuticals No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. W. Carlson
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - C. M. Schurman
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - E. Rivera
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - C. T. Chung
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - S. C. Phan
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - E. K. Dice
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - E. Thomas
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| | - V. Valero
- Stanford Univ, Stanford, CA; MD Anderson Cancer Cntr, Houston, TX
| |
Collapse
|
32
|
Rivera E, Cremaschi G, Genaro AM, Croci M, Sambuco L, Cricco G, Martin G, Bergoc R, Crescenti E. Actions of a novel therapeutic formulation: Zn, Se and Mn plus Lachesis Muta venom (O-LM) on radiation deleterious immune effects. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14116 Background: We have previously reported that O-LM inhibits malignant cell proliferation and increases survival in rodent tumor models (Int J Cancer S13:183, 2002). Molecular and immunological basis of O-LM action were reported (J Clin Oncol 24:18S, 2006). As O- LM selectively protects normal tissues from high doses of ionizing radiation (Proc Int Cancer Congress,1495–9, 1998), we here investigated O- LM protective action upon radiation effects on immune cells. Methods: Balb/c mice (n=15 each group) were employed: control (C); 2Gy whole body irradiated (IR); treated with O-LM (Zn, Se, Mn 4μg/ml each; L. Muta 4 ng/ml; 0.1 ml/day, sc) for 15 days and 2Gy irradiated (O-LM+IR). Mice were sacrificed at day 3, 7 or 15 post-irradiation (PI). Proliferation was evaluated in lymphocytes by [3H]- Thymidine incorporation after T- or B selective mitogen stimulation. In cell-free supernatants (SN) from mitogen-stimulated cultures cytokines involved in lymphocyte regulation and/or inflammation were determined by ELISA. Results: Irradiation induced a decrease in T lymphocyte proliferation at 3 and 7 days PI (% of decrease in IR: 47.6±9.0, p<0.05; 42.0±7.2, p<0.02 respectively). Pretreatment with O-LM recovered proliferation to basal values (day 3 PI 93.4±10.2%; day 7 PI 130.9±15.3%, O-LM+IR vs. C; p=NS). No modifications were observed in B cells. At day 3 PI, a marked decrease in IFN? levels was obtained in SN of IR mice that was reverted by O-LM treatment (pg/ml: IR 1653±419; C 10884±2783, p<0.02; O-LM+IR 16924±4284, p<0.05 vs C). Also, at day 7 PI, an important increase in TNFa was observed in IR mice, that were reverted by O-LM (pg/ml: IR: 300.7±62.3 vs O-LM+IR: 28.7±2.3, p<0.02). No differences were found in IL-2 levels. Conclusions: The therapeutic action of O-LM is based on its ability of targeting simultaneously multiple pathways involved in cancer development. Present data demonstrate that O-LM protects animals from irradiation by recovering the immune function, improving T lymphocyte activity and modulating the production of key cytokines as IFN? and TNFa. The reported effect may represent a potential benefit for cancer patients undergoing radiotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Rivera
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - G. Cremaschi
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - A. M. Genaro
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - M. Croci
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - L. Sambuco
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - G. Cricco
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - G. Martin
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - R. Bergoc
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| | - E. Crescenti
- University of Buenos Aires, School of Pharmacy, Buenos Aires, Argentina; Institute of Immuno Oncology, Buenos Aires, Argentina
| |
Collapse
|
33
|
Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2007; 17:1424-7. [PMID: 16966368 DOI: 10.1093/annonc/mdl141] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Rituximab is associated with low incidence of hypogammaglobulinemia and little morbidity. Our experience with the combination of rituximab + chemotherapy suggested the opposite. PATIENTS AND METHODS We analyzed our experience with rituximab plus chemotherapy in 97 patients to determine: frequency and type of non-neutropenic infection (NNI); frequency and type of hypogammaglobulinemia; response to gammaglobulin therapy; and factors associated with NNI. RESULTS We observed 40 episodes of NNI in 19 of 97 (20%) patients. By 3 years, 43% of patients treated with rituximab + chemotherapy were projected to have developed at least one NNI. Of 19 with NNI, 15 had Ig levels studied and all 15 had hypogammaglobulinemia. Most frequently affected Ig were IgG (14 of 15) and IgM (13 of 14). IgA was usually spared (six of 14 cases affected). NNIs observed were 18 bronchitis, 16 sinusitis, four pneumonias, three otitis media, two fevers of unknown origin (FUOs) and three herpes zoster. Hospitalization was required in seven of 19. Ten received gammaglobulin infusions and all responded promptly. Gammaglobulin was given only when NNIs recurred. We examined sex, age, histology, type of rituximab-chemotherapy (fludarabine + rituximab versus other chemotherapy + rituximab) for correlation with NNI. CONCLUSIONS Indolent histology, female sex and fludarabine + rituximab significantly correlated with frequency of NNI but multivariate analysis picked fludarabine + rituximab followed by female gender as the only two independent variables predictive of NNI.
Collapse
Affiliation(s)
- F Cabanillas
- Auxilio Mutuo Cancer Center, Hospital Auxilio Mutuo, San Juan, Puerto Rico.
| | | | | | | |
Collapse
|
34
|
Cohen L, Chandwani K, Thornton B, Perkins G, Rivera E, Arun B, Raghuram N, Nagendra H. Randomized trial of yoga in women with breast cancer undergoing radiation treatment. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8505] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8505 Background: Yoga, an ancient Indian science, incorporates stress-reduction techniques that include regulated breathing, visual imagery, and meditation, as well as various postures that may be useful for cancer patients. Methods: A yoga program was developed that including loosening and breathing exercises, postures, alternate nostril breathing, a deep relaxation technique, and meditation for patients with breast cancer who were undergoing radiotherapy. Women participated in bi-weekly classes during their 6 weeks of radiation treatment. Sixty-one women with breast cancer were randomly assigned to either the yoga program or to a waitlist control group. Patients completed measures of intrusive thoughts and avoidance behaviors (Impact of Events Scale: IES), depressive symptoms (CES-D), sleep disturbances (Pittsburgh Sleep Quality Index), fatigue (BFI), and quality of life (SF-36) at baseline, 1 week, and 1 and 3 months after the last radiation therapy. We report on the outcomes 1 week after the end of radiotherapy. Results: The average age of the women was 52, 3% stage 0, 28% stage I, 43% stage II, and 26% stage III, 48% had undergone breast-conserving surgery, and 75% had received chemotherapy prior to starting radiotherapy. Analysis of covariance, controlling for baseline, revealed that the yoga group had significantly better SF-36 physical function scores (adjusted means: yoga 81.8 vs. control 68.6, P < 0.01), significantly higher SF-36 general health scores (adjusted means: yoga 78.3 vs. control 67.9, P < 0.03), marginally better SF-36 social functioning scores (adjusted means: yoga 85.3 vs. control 76.0, P > 0.1), significantly lower levels of sleep-related daytime dysfunction (adjusted means: yoga 0.5 vs. control 1.2, P < 0.04), and marginally lower levels of fatigue (adjusted means: yoga 1.9 vs. control 3.1, P < 0.06) than the control group. There were no other group differences on the SF-36 subscales or for the CES-D or IES scores. Conclusions: The results indicated that the yoga program was associated with statistically and clinical significant improvements in aspects of quality of life. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Cohen
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - K. Chandwani
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - B. Thornton
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - G. Perkins
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - E. Rivera
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - B. Arun
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - N. Raghuram
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| | - H. Nagendra
- UT M. D. Anderson Cancer Center, Houston, TX; Swami Vivekananda Yoga Anusandhana Samsthana, Bangalore, India
| |
Collapse
|
35
|
Gore L, Rivera E, Lavallee K, Holden S, Grolnic S, Cleere D, Moulder SL, Elsayed YA, Eckhardt S. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2079 Background: T binds to the minor groove of DNA, synergizes with functional nuclease excision repair and targets inducible transcription. T is active in several tumor types and exhibits preclinical synergy with C. The primary objective of this study is to determine the maximum tolerated dose (MTD) of T in combination with C. Secondary objectives include safety and pharmacokinetic (PK) analyses. Methods: Pts with advanced cancer, performance status 0–1 and adequate organ function are eligible. Pts received T starting at 0.4 mg/m2 over 3 hours on day 1 followed by C on days 2 through 15. The initial dose of C was 2000 mg/m2/day and was reduced to 1600 mg/m2/day due to GI dose-limiting toxicity. Dose escalation of T continued. Cycles are repeated every 3 weeks, with PK sampling included. Standard “3+3” dose escalation design, definitions of dose limiting toxicity (DLT), and dose modification for toxicity are implemented. Results: To date, 30 patients have received 112 cycles (range 1–12, median 4) of treatment at 7 dose levels. Two of 3 pts at dose level 4 (C 2000 mg/m2/d and T 0.9 mg/m2) and 2/6 pts at dose level 3 (C 2000 mg/m2/d and T 0.75 mg/ m2) developed gastrointestinal DLT (emesis, diarrhea, pancreatitis). C was subsequently reduced to 1600 mg/m2/d and a new T dose escalation was initiated at 0.6 mg/m2. Treatment has been well tolerated with C 1600 mg/m2/d and T up to the current dose of 0.9 mg/m2 (dose level 4a), with 1of 6 subjects experiencing grade 1 alkaline phosphatase. The most frequently reported related grade 3–4 adverse events (AEs) are diarrhea (23%), neutropenia (20%), nausea (16.6%), hand-foot syndrome (16.6%) and vomiting (13%). Anti-tumor activity to date includes a confirmed partial response lasting 8 months (m) in a patient with cholangiocarcinoma, and prolonged stable disease in 2 patients with breast cancer (6 and 7m), ovarian cancer (11m) and chondrosarcoma (9m). Conclusions: The combination of C 1600mg/m2/d and T up to 0.9mg/m2 is tolerable and has promising activity in several tumor types. Dose escalation of T continues at 1.1 mg/m2. Biologic and pharmacokinetic analyses will be presented. [Table: see text]
Collapse
Affiliation(s)
- L. Gore
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - E. Rivera
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - K. Lavallee
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - S. Holden
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - S. Grolnic
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - D. Cleere
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - S. L. Moulder
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - Y. A. Elsayed
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| | - S. Eckhardt
- University of Colorado Cancer Center, Aurora, CO; Johnson & Johnson Pharmaceutical R & D, Raritan, NJ; UT M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
36
|
Rivera E, Mejia JA, Arun B, Adinin R, Walters R, Brewster A, Broglio K, Yin G, Esteva FJ, Hortobagyi GN, Valero V. Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
574 Background: D is a semi-synthetic taxane with significant activity in breast cancer. D is usually administered on an every 3-weeks schedule, however, studies have demonstrated drug efficacy and a different toxicity profile when administered on a weekly basis. In this study we compared the weekly schedule versus every 3-weeks to define the safest schedule with the highest efficacy. Methods: Patients (Pts) were enrolled if they had stage IV breast cancer and had received no more than one prior chemotherapy regimen for metastatic disease. Prior treatment with D was not allowed but adjuvant paclitaxel (P) was allowed if > 12 months since the last dose. Pts were randomized to receive D at a starting dose of 75mg/m2 on day 1 or DW at a dose of 35 mg/m2/week for 3 weeks followed by 1 week of rest every 28 days. Doses could be escalated to 100 mg/m2 and 40mg/m2, respectively at the discretion of the investigator. Premedication with dexamethasone was given with each regimen. Results: From 1/2001 until 9/2004, a total of 125 pts were enrolled, 63 in the DW arm and 62 in the D arm. Thirty-nine and 10 pts had received prior anthracycline (A) and P respectively in the D arm while 32 and 11 pts had A and P in the DW arm. Median ages were 56 and 54 years in the D and DW arm, respectively. 118 pts were eligible for an efficacy analysis with a response rate of 35.6%; (95% CI, 23.6%, 49.1%) for the D arm vs 20.3%; (95% CI, 11.0%, 32.8%) for DW. There was no difference between D and DW in median PFS and OS, 5.7 vs 5.5 months (p = 0.46) and 18.3 vs 18.6 months (p = 0.34), respectively. There was a higher overall toxicity rate (grade 3 and 4) in the D arm vs DW, 88.1% vs 55.9% (p = 0.0001). There were 48 (81%) and 6 (10%) pts with grade ¾ granulocytopenia with 6 (10%) and 2 (3%) episodes of neutropenic fever in D vs DW, respectively. Grade 3/4 fatigue and myalgias were reported more often in D than DW, 15 (25%) and 8 (13.5%), and 16 (27%) and 2 (3%), respectively. Grade 3 epiphora was similar in both arms, 4 (7%) and 5 (8%) for D and DW, respectively. Conclusions: D has a higher response rate compare to DW but with a more pronounced toxicity profile. This needs to be kept in mind when making a treatment recommendation for patients with metastatic breast cancer. No difference in PFS or OS was observed between both arms. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Rivera
- M.D. Anderson Cancer Center, Houston, TX
| | | | - B. Arun
- M.D. Anderson Cancer Center, Houston, TX
| | - R. Adinin
- M.D. Anderson Cancer Center, Houston, TX
| | - R. Walters
- M.D. Anderson Cancer Center, Houston, TX
| | | | - K. Broglio
- M.D. Anderson Cancer Center, Houston, TX
| | - G. Yin
- M.D. Anderson Cancer Center, Houston, TX
| | | | | | - V. Valero
- M.D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
37
|
Amin SR, Valero V, Rivera E, Adinin R, Banay R, Arbuckle R, Do K, Esmaeli B. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
659 Background: To determine the incidence and severity of epiphora and canalicular stenosis in patients receiving weekly or every-3-weekly docetaxel. Methods: In this prospective trial, each patient underwent an ophthalmologic examination and probing and irrigation of the lacrimal drainage apparatus at baseline and at every 4–6 weeks after initiation of docetaxel. During each visit, epiphora and canalicular stenosis were graded. Patients with epiphora were treated with Tobradex drops. If epiphora worsened or findings on probing and irrigation suggested further canalicular narrowing, silicone intubation was offered. Results: 28 patients received weekly and 28 patients received every-3-weeks docetaxel. 18(64%) patients who received weekly docetaxel developed epiphora. Epiphora was mild in 7 patients, moderate in 5, and severe in 6. Nine patients had resolution of epiphora with Tobradex. Nine patients had worsened canalicular stenosis; 6 underwent surgery. The median cumulative docetaxel dose was 496.5 mg at onset of epiphora and 889.5 mg at surgery. 11 (39%) patients who received every-3-weeks docetaxel developed epiphora. The median cumulative docetaxel dose at the time of onset of epiphora in this group was 420 mg. Epiphora was mild in 9 patients, moderate in 1, and severe in 1. Nine patients had resolution of epiphora in response to Tobradex. Two patients underwent surgery. Conclusions: Epiphora occurred in 64% of patients in the weekly group and 39% of patients in the every-three-weeks group. Moderate or severe canalicular stenosis was seen in about one-third of patients in the weekly group and none of the patients in the every-3-weeks group. [Table: see text]
Collapse
Affiliation(s)
- S. R. Amin
- M. D. Anderson Cancer Center, Houston, TX
| | - V. Valero
- M. D. Anderson Cancer Center, Houston, TX
| | - E. Rivera
- M. D. Anderson Cancer Center, Houston, TX
| | - R. Adinin
- M. D. Anderson Cancer Center, Houston, TX
| | - R. Banay
- M. D. Anderson Cancer Center, Houston, TX
| | | | - K. Do
- M. D. Anderson Cancer Center, Houston, TX
| | - B. Esmaeli
- M. D. Anderson Cancer Center, Houston, TX
| |
Collapse
|
38
|
Cabanillas F, Liboy I, Rodriguez-Monge E, Pavia O, Robles N, Maldonado N, Rivera E, Suau L. A dose dense low toxicity salvage regimen for histologically aggressive non-Hodgkin’s lymphoma (NHL): Gemcitabine, rituximab, oxaliplatin combination (GROC) plus pegfilgrastim. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17513] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17513 High dose chemo/autologous stem cell transplant (ASCT) is standard treatment for relapsed aggressive NHL. However many are unable to receive ASCT because they are refractory to salvage therapy, too old or too sick. More effective, less toxic salvage regimens are needed prior to ASCT. Gemcitabine (G) and Oxaliplatin (O) are active agents in NHL and exhibit synergism so their combination is attractive to explore together with Rituximab (R). We hereby report the results of a phase I-II trial designed to explore the GROC regimen administered every 14 days with Pegfilgrastim support. After the first 6 pts were entered, the phase I portion was completed; recommended dose: R = 375 mg/m2 on day 1, G = 1,250 mg/M2 on day 2, O = 100 mg/m2 on day 2 and Neulasta 6 mg day 3. So far we have entered 21 pts of which 19 are currently evaluable. Median age = 58 (range = 27–88); 9 were refractory to 1st line therapy, 5 were on 1st relapse, 3 on 2nd and 2 >2 relapses, 12 had high LDH, 10 high Beta-2-M. Using IWG/PET criteria ORR = 79%, CR = 42%, PR = 37%. There was a correlation between response to preceding chemo regimen and response to GROC ( table ). In 6 the response to GROC was better than to preceding regimen while only in 2 was the response worse. At 1 year the projected OS is 49% and PFS 34%. So far, only 5 of 15 responders have relapsed. An intriguing finding is that in 6 of 15 responders, PFS has been longer with GROC than with preceding regimen and shorter in only 1. Grade 4 hematologic toxicity occurred only once. No neutropenic fevers seen. Most common toxicity was reversible transaminitis in 13 (grade 1–2 in 10, grade 3 in 3), neuropathy in 9 (grade 1–2 in 8, grade 3 in 1), diarrhea in 3 (grade 4 in 1). We could deliver courses at a median interval of 14 days. Conclusions: 1- GROC is an effective dose dense salvage regimen. 2- It appears effective even in pts with poor prognostic features including primary refractory disease. 3-Hematologic toxicity is very low and non-hematologic toxicity acceptable. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- F. Cabanillas
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - I. Liboy
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - E. Rodriguez-Monge
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - O. Pavia
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - N. Robles
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - N. Maldonado
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - E. Rivera
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| | - L. Suau
- Auxilio Mutuo Cancer Center, San Juan; Puerto Rico Oncology Consortium, San Juan, Puerto Rico; Auxilio Mutuo Cancer Center, San Juan, Puerto Rico; Puerto Rico Chemotherapy Consortium, San Juan, Puerto Rico
| |
Collapse
|
39
|
Cricco G, Núñez M, Medina V, Garbarino G, Mohamad N, Gutiérrez A, Cocca C, Bergoc R, Rivera E, Martín G. Histamine modulates cellular events involved in tumour invasiveness in pancreatic carcinoma cells. Inflamm Res 2006; 55 Suppl 1:S83-4. [PMID: 16705385 DOI: 10.1007/s00011-005-0054-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- G Cricco
- Radioisotopes Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Junín 956 PB (C1113AAB), Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Rivera E, Ekholm Pettersson F, Inganäs M, Paulie S, Grönvik KO. The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine 2005; 23:5411-9. [PMID: 16286158 DOI: 10.1016/j.vaccine.2005.04.007] [Citation(s) in RCA: 87] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2002] [Revised: 12/01/2004] [Accepted: 04/11/2005] [Indexed: 11/19/2022]
Abstract
Porcine parvovirus (PPV) vaccines containing different adjuvants were evaluated for inducing Th1 or Th2 type of immunity in mice. Isotypes of antigen specific antibodies and levels of cytokines in serum and in lymphocyte culture supernatants measured by ELISA and the Gyrolab Bioaffy were used to determine the polarisation of the immune response. Enumeration of cytokine secreting cells was carried out by ELISPOT assays. Vaccines containing the ginseng-fraction Rb1 induced serum-detectable amounts of IL-4 and IL-10 as early as 24h after primary injection that was confirmed in sera collected at 24 and 72 h post re-vaccination. Five weeks after booster, immune lymphocytes were still producing large amounts of cytokines including IFN-gamma, IL-2, IL-4, IL-10 and TNF-alpha and the antibody titres were still similar to those titres recorded 1 week post booster. The Rb1 adjuvanted vaccines stimulated similar titres of antigen specific IgG1, IgG(2a) and IgG(2b). Thus, the cytokine and the serological data indicated that the Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response.
Collapse
Affiliation(s)
- E Rivera
- National Veterinary Institute, Department of Vaccine Research, P.O. Box 7073, SE-751 89 Uppsala, Sweden.
| | | | | | | | | |
Collapse
|
41
|
Michaud LB, Rivera E, Madden T, Esparza-Guerra L, Booser DJ, Green MC, Bradshaw GR, Hortobagyi GN, Valero V. Taxanes in metastatic breast cancer patients with impaired liver function. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - E. Rivera
- M.D. Anderson Cancer Ctr, Houston, TX
| | - T. Madden
- M.D. Anderson Cancer Ctr, Houston, TX
| | | | | | | | | | | | - V. Valero
- M.D. Anderson Cancer Ctr, Houston, TX
| |
Collapse
|
42
|
Medina V, Cricco G, Mohamad N, Croci M, Núñez M, Martín G, Cocca C, Bergoc R, Rivera E. Histamine is a selective protector against cellular damage produced by ionizing radiation. Inflamm Res 2005; 54 Suppl 1:S17-8. [PMID: 15928816 DOI: 10.1007/s00011-004-0407-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Affiliation(s)
- V Medina
- Laboratorio de Radioisótopos Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 PB, 1113, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Esteva FJ, Madden TL, Lammey J, Symmans WF, Booser DJ, Arun B, Rivera E, Brewster AM, Valero V, Hortobagyi GN. Phase I and pharmacokinetic (PK) study of oblimersen, a proapoptotic Bcl-2 targeting oligonucleotide, in combination with doxorubicin and docetaxel in metastatic and locally advanced breast cancer (BC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. J. Esteva
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - T. L. Madden
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - J. Lammey
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - D. J. Booser
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - B. Arun
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | - E. Rivera
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | | - V. Valero
- U Texas M. D. Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
44
|
Cricco G, Martín G, Medina V, Núñez M, Gutiérrez A, Cocca C, Bergoc R, Rivera E. Histamine regulates the MAPK pathway via the H(2) receptor in PANC-1 human cells. Inflamm Res 2004; 53 Suppl 1:S65-6. [PMID: 15054622 DOI: 10.1007/s00011-003-0331-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2003] [Accepted: 01/01/2003] [Indexed: 01/15/2023] Open
Affiliation(s)
- G Cricco
- Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956 PB, 1113 Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|
45
|
de la Monte SM, Chen GJ, Rivera E, Wands JR. Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 2004; 60:2679-91. [PMID: 14685691 DOI: 10.1007/s00018-003-3305-3] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
In Alzheimer's disease (AD), neuronal thread protein (NTP) accumulates in cortical neurons and colocalizes with phospho- tau-immunoreactive cytoskeletal lesions that correlate with dementia. To generate additional information about the potential role of NTP in AD, we characterized its expression and regulation in human SH-Sy5y neuronal cells. Quantitative real-time reverse transcription-polymerase chain reactin and Western blot analysis demonstrated prominent insulin, moderate insulin-like growth factor, type 1 (IGF-1) and minimal nerve growth factor stimulation of NTP expression. In addition, NTP protein was more stable and it progressively accumulated in cells that were stimulated with insulin for 24 or 48 h. Metabolic labeling and phospho-amino acid analysis demonstrated phosphorylation of NTP on Serine residues, 30-60 min after insulin or IGF-1 stimulation, when glycogen synthase kinase 3beta (GSK-3beta) activity would no longer have been suppressed. Kinase inhibitor and in vitro phosphorylation studies demonstrated a role for GSK-3beta in the positive regulation of NTP expression and phosphorylation. Coimmunoprecipitation studies demonstrated physical interactions between NTP and tau or microtubule-associated protein 1b (MAP-1b), and ubiquitin immunoreactivity in NTP immunoprecipitates. In summary, these studies showed that (i) NTP expression is regulated at the level of transcription by insulin and IGF-1 stimulation; (ii) NTP is phosphorylated by GSK-3beta; (iii) NTP can physically interact with tau and MAP-1b and (iv) NTP-MAP complexes are ubiquitinated. The results suggest a functional role for NTP in relation to the turnover or processing of neuronal cytoskeletal proteins, attributes that may be modulated by insulin/IGF-1-mediated signaling.
Collapse
Affiliation(s)
- S M de la Monte
- Department of Medicine, Rhode Island Hospital and Brown Medical School, 55 Claverick Street, Providence, Rhode Island 02903, USA.
| | | | | | | |
Collapse
|
46
|
|
47
|
Abstract
The dry extract prepared from the Panax ginseng C.A. Meyer-root (total ginseng (T-ginseng)) contain ginsenosides (G-des) which were shown to have adjuvant properties as demonstrated by: (a) injecting guinea pigs with a mixture of T-ginseng and inactivated porcine parvovirus (PPV) as a conventional vaccine; (b)injecting PPV-antigen and T-ginseng simultaneously but separately at different sites on the animal and (c)injecting only the T-ginseng 1 or 2 weeks prior to immunisation with the PPV-antigen. Using a haemagglutination inhibition (HI) test in the antibody titration, it was found that the mean HI-titre for the animals injected with PPV-antigen only was 320 +/- 0. By comparison, the mean titre value was 2026 +/- 1206 for the sera from the animals injected with the same vaccine but adjuvanted with 4 mg of T-ginseng, while the antibody titre induced by a vaccine containing Al(OH)(3)-gel was 2986 +/- 1596. Interestingly, the T-ginseng and Al(OH)(3) acted synergistically and further improved the antibody response to the PPV-antigen to 6826 +/- 2413, i.e. more than 20 times the HI titre of the non-adjuvanted PPV-vaccine. Immunisations using PPV-vaccines adjuvanted with single purified G-des demonstrated that the ginseng fractions Rb1 and Rg1 are potent adjuvants inducing higher or similar antibody titres than the vaccine adjuvanted with Al(OH)(3), e.g. Rb1 tested at a concentration of 830 microg per dose induced a significantly (P = 0.009) higher antibody titre than the one adjuvanted with Al(OH)(3). Nevertheless, different than the mixture Al(OH)(3)-T-ginseng; Rb1 and Rg1 act antagonistically and partially inhibit each other. The G-des adjuvanted vaccines induced significantly (P = 0.0011) higher titres of IgG2 antibodies compared with IgG1.
Collapse
Affiliation(s)
- E Rivera
- National Veterinary Institute, Uppsala S-751 89, Sweden.
| | | | | |
Collapse
|
48
|
Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 2003; 91:19-27. [PMID: 12507846 DOI: 10.1016/s0165-2427(02)00269-6] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Ginseng, the dry extract prepared from the Panax ginseng C.A. Mayer-root contain immunomodulators named ginsenosides, which in the pig enhance the antibody response to viral and bacterial antigens. The enhancing effect of ginseng was demonstrated vaccinating pigs against porcine parvovirus (PPV) and Erysipelothrix rhusiopathiae infections, using commercially available vaccines. The potency of the licensed, aluminium hydroxide adjuvanted; vaccines were compared with those supplemented with ginseng. The antibody response to PPV was measured by the haemagglutination inhibition (HI) test whereas the mouse potency test and ELISA evaluated the immune response to E. rhusiopathiae. Antibodies to the 64-66 kDa glycoprotein of the E. rhusiopathiae were demonstrated by immunoblotting. The qualitative antibody responses were evaluated by means of ELISA(s) using monoclonal antibodies to swine IgG1 and IgG2. The addition of 2mg ginseng per vaccine dose, potentiate the antibody response of the commercial vaccines without altering their safety. Significantly higher (P<0.001) antibody titres were achieved to both PPV and to E. rhusiopathiae by the supplementation with ginseng. Aluminium hydroxide adjuvanted vaccines favoured the production of IgG1 antibodies. Interestingly, the vaccines supplemented with ginseng favoured IgG2. The vaccines used in the evaluations varied in their immunogenic potency. However, after the addition of ginseng the less immunogenic vaccine proved to be as potent as the better one without ginseng. Thus, the use of ginseng as a co-adjuvant provides a simple, safe and cheap alternative for improving the potency of aluminium hydroxide adjuvanted vaccines.
Collapse
Affiliation(s)
- E Rivera
- Department of Vaccine Research, National Veterinary Institute, SE-751 89 Uppsala, Sweden.
| | | | | |
Collapse
|
49
|
Szincsák N, Hegyesi H, Hunyadi J, Martin G, Lázár-Molnár E, Kovács P, Rivera E, Falus A, Juhász I. Cimetidine and a tamoxifen derivate reduce tumour formation in SCID mice xenotransplanted with a human melanoma cell line. Melanoma Res 2002; 12:231-40. [PMID: 12140379 DOI: 10.1097/00008390-200206000-00006] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Histamine is produced by many cells expressing histidine decarboxylase (HDC), the enzyme responsible for the synthesis of histamine. Since melanoma cells and tissue contain relatively large amounts of histamine, the functional significance of histamine was examined using specific antihistamines in vitro and in vivo in the human melanoma cell line HT168 and severe combined immunodeficiency (SCID) mice. It was shown that the H2 receptor antagonist cimetidine when combined with N, N-diethyl-2-[4-(phenylmethyl)phenoxy]-ethanamine-HCl (DPPE), a tamoxifen derivate, inhibits the proliferation of HT168 cells. Furthermore, it is suggested that there is a factor(s) that interferes with the exponential growth of HT168 cells xenografted to immunodeficient mice, and cimetidine and DPPE together significantly influence this factor(s). This combination of antihistamines also increases the survival of human melanoma-grafted mice. These changes are accompanied by enhanced infiltration of interferon-gamma- producing mouse macrophages into the tumour tissue. These findings suggest that two different mechanisms are probably acting concordantly: direct inhibition of tumour cell proliferation by the H2 receptor antagonists, and activation of the local immune response characterized by interferon-gamma production. These findings may help to elucidate the possibility of a rationally designed antihistamine strategy in melanoma therapy.
Collapse
Affiliation(s)
- N Szincsák
- Department of Dermatology, Debrecen University, Debrecen, Hungary
| | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Martín G, Cricco G, Darvas Z, Croci M, Núñez M, Bergoc R, Falus A, Rivera E. Histamine inhibits proliferation of a pancreatic carcinoma cell line without inducing apoptosis significantly. Inflamm Res 2002; 51 Suppl 1:S67-8. [PMID: 12013415 DOI: 10.1007/pl00022452] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- G Martín
- Laboratorio de Radioisótopos, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina
| | | | | | | | | | | | | | | |
Collapse
|